What is the main purpose of this 8-K filing by Vertex Pharmaceuticals?

The main purpose of this 8-K filing is to provide certifications from the company's principal executive and financial officers, as required by Section 906 of the Sarbanes-Oxley Act of 2002, in support of their recently filed Quarterly Report on Form 10-Q for the period ending June 30, 2002. It signifies compliance with new regulatory mandates.

Does this 8-K contain new financial results for Vertex Pharmaceuticals?

No, this specific 8-K filing does not contain new financial results. It is a procedural document related to certifications accompanying their Form 10-Q for the quarter ending June 30, 2002.

What is the Sarbanes-Oxley Act of 2002, and why is it relevant here?

The Sarbanes-Oxley Act of 2002 is a federal law that mandates certain corporate governance and financial reporting standards. Section 906 requires CEOs and CFOs to certify the accuracy of financial reports. This filing indicates Vertex's adherence to these new disclosure requirements.

Who are Joshua S. Boger and Ian F. Smith?

Joshua S. Boger is the Chief Executive Officer (CEO) of Vertex Pharmaceuticals, and Ian F. Smith is the Chief Financial Officer (CFO). Their certifications are part of the company's compliance with the Sarbanes-Oxley Act.

VRTX 8-K SEC Disclosure

Summary

Vertex Pharmaceuticals Incorporated (VRTX) filed a Current Report on Form 8-K on August 14, 2002, to disclose information related to their second quarter 2002 financial reporting. The primary purpose of this filing was to provide updated certifications from the company's principal executive officer, Joshua S. Boger, and principal financial officer, Ian F. Smith, as required by Section 906 of the Sarbanes-Oxley Act of 2002, in conjunction with their Quarterly Report on Form 10-Q for the period ending June 30, 2002. This filing is procedural, indicating compliance with new regulatory requirements.

Key Highlights

1Vertex Pharmaceuticals filed an 8-K on August 14, 2002.
2The filing pertains to the Quarterly Report on Form 10-Q for the period ending June 30, 2002.
3Key information disclosed relates to certifications required by Section 906 of the Sarbanes-Oxley Act of 2002.
4The certifications were provided by CEO Joshua S. Boger and CFO Ian F. Smith.
5This filing demonstrates Vertex's compliance with new post-Sarbanes-Oxley regulatory requirements.
6No new financial results or significant business updates are presented in this specific 8-K filing itself.

VERTEX PHARMACEUTICALS INC / MA 8-K Report (Aug 14, 2002)

Summary

Key Highlights

Frequently Asked Questions